...
首页> 外文期刊>European archives of oto-rhino-laryngology: Official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) >Prognostic value of preoperative 18F-FDG PET/CT for primary head and neck squamous cell carcinoma.
【24h】

Prognostic value of preoperative 18F-FDG PET/CT for primary head and neck squamous cell carcinoma.

机译:术前18F-FDG PET / CT对原发性头颈部鳞状细胞癌的预后价值。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

(18)F-FDG PET/CT is clinically useful in the initial staging and follow-up of patients with head and neck squamous cell carcinoma (HNSCC). We studied the potential prognostic significance of preoperative (18)F-FDG PET/CT in HNSCC. The medical records of 294 patients who underwent preoperative (18)F-FDG PET/CT for HNSCC were retrospectively reviewed. The median SUVmax of the primary lesions (SUVmax-p) and cervical lymph nodes (SUVmax-n) was 7.98 ± 5.04 (range 1.2-28.7) and 3.34 ± 3.70 (range 1.0-20.4), respectively. There was a significant difference between with and without recurrence in SUVmax-p (11.14 ± 5.36 vs. 6.78 ± 4.35, p < 0.001) and SUVmax-n (5.60 ± 4.22 vs. 1.75 ± 1.46, p < 0.001). The cut-off values of SUVmax-p and SUVmax-n in the context of recurrence and cancer-related death were 8.5 and 3.5. The 5-year disease-free survival of patients with SUVmax-p < 8.5 and SUVmax-n < 3.5 was 79 and 79%, respectively, whereas that of patients with SUVmax-p ≥ 8.5 and SUVmax-n ≥ 3.5 was 39 and 30 %, respectively. Multivariate analysis confirmed the significant association between 5-year disease-free survival and SUVmax-p ≥ 8.5 (hazard ratio (HR) 2.68, p < 0.001) and SUVmax-n ≥ 3.5 (HR 2.29, p = 0.007). Furthermore, SUVmax-p ≥ 8.5 (HR 3.20, p = 0.012) and SUVmax-n ≥ 3.5 (HR 2.14, p < 0.001) were associated with 5-year overall survival. (18)F-FDG PET/CT cut-off values of SUVmax-p ≥ 8.5 or SUVmax-n ≥ 3.5 are associated with a recurrence and survival in HNSCC.
机译:(18)F-FDG PET / CT在头颈鳞状细胞癌(HNSCC)患者的初始分期和随访中具有临床意义。我们研究了HNSCC术前(18)F-FDG PET / CT的潜在预后意义。回顾性分析了294例行HNSCC术前(18)F-FDG PET / CT的患者的病历。主要病变的中位SUVmax(SUVmax-p)和宫颈淋巴结中位SUVmax(SUVmax-n)分别为7.98±5.04(范围1.2-28.7)和3.34±3.70(范围1.0-20.4)。 SUVmax-p(11.14±5.36 vs. 6.78±4.35,p <0.001)和SUVmax-n(5.60±4.22 vs. 1.75±1.46,p <0.001)在有复发和无复发之间存在显着差异。在复发和癌症相关死亡的背景下,SUVmax-p和SUVmax-n的临界值为8.5和3.5。 SUVmax-p <8.5和SUVmax-n <3.5的5年无病生存率分别为79%和79%,而SUVmax-p≥8.5和SUVmax-n≥3.5的患者的5年无病生存率分别为39和30。 %, 分别。多变量分析证实了5年无病生存率与SUVmax-p≥8.5(危险比(HR)2.68,p <0.001)和SUVmax-n≥3.5(HR 2.29,p = 0.007)之间存在显着相关性。此外,SUVmax-p≥8.5(HR 3.20,p = 0.012)和SUVmax-n≥3.5(HR 2.14,p <0.001)与5年总生存期相关。 (18)SUVmax-p≥8.5或SUVmax-n≥3.5的F-FDG PET / CT临界值与HNSCC的复发和生存有关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号